Biosimilar biologic drugs: a new frontier in medical care

Postgraduate Medicine

Volumn 129, Issue 4, 2017, Pages 460-470

  Geynisman, Daniel M ^a   De Velasco, Guillermo ^b,c   Sewell, K Lea ^d   Jacobs, Ira ^d  

^a TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d PFIZER INC   (United States)

Author keywords

biologic therapy; Biosimilars; drug development; regulatory approval

Indexed keywords

ADALIMUMAB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; CARBOPLATIN; ETANERCEPT; FILGRASTIM; FLUOROPYRIMIDINE; FLUOROURACIL; GP 2013; HUMAN GROWTH HORMONE; INFLIXIMAB; INSULIN GLARGINE; MYL 1401 O; OXALIPLATIN; PACLITAXEL; PEGFILGRASTIM; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT FOLLITROPIN; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOGENICITY; MEDICAL CARE; PACKAGING; PATIENT RIGHT; PRACTICE GUIDELINE; QUALITY CONTROL; REVIEW; TOXICITY; EVIDENCE BASED MEDICINE; UNITED STATES;

BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; EVIDENCE-BASED MEDICINE; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85017031130     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.1080/00325481.2017.1311196     Document Type: Review

References (77)

1. US Food and Drug Administration. Drugs@FDA glossary of terms. Silver Spring (MD):US Department of Health and Human Services; 2012 [updated 2012 Feb 2; cited 2016 Dec 20]. Available from:http://www.fda.gov/drugs/informationondrugs/ucm079436.htm#B
2. Generics and Biosimilars Initiative (GaBi) Online. Small molecule versus biological drugs. Mol:Pro PharmaCommunications International; 2012 [updated 2012 Jun 29; cited 2016 Dec 20]. Available from:http://www.gabionline.net/Biosimilars/Research/Small-molecule-versus-biological-drugs
3. Medscape Medical News. 100 Best-selling, most prescribed branded drugs through June. New York (NY):WebMD LLC; 2015 [updated 2015 Aug15; cited 2016 Dec 20]. Available from:http://www.medscape.com/viewarticle/849457
4. Mocsai A, Kovacs L, Gergely P., What is the future of targeted therapy in rheumatology:biologics or small molecules? BMC Med. 2014;12:43. Epub 2014/03/14
5. Monaco C, Nanchahal J, Taylor P, et al. Anti-TNF therapy:past, present and future. Int Immunol. 2015;27:55–62. Epub 2014/11/21
6. Siebert S, Tsoukas A, Robertson J, et al. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol Rev. 2015;67:280–309. Epub 2015/02/24
7. Sridharan M, Hubbard JM, Grothey A. Colorectal cancer:how emerging molecular understanding affects treatment decisions. Oncology (Williston Park, N.Y.). 2014;28:110–118. Epub 2014/04/08
8. F. Hoffmann-La Roche Ltd. MabThera (rituximab) summary of product characteristics. Basel:European Medicines Agency; 2008 [updated 2016 Aug 2; cited 2016 Nov 9]. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf
9. Genentech Inc. Rituxan® (rituximab) prescribing information. South San Francisco (CA); 1997 [updated 2016 Apr; cited 2016 Dec14]. Available from:http://www.gene.com/download/pdf/rituxan_prescribing.pdf
10. Genentech Inc. Avastin® (bevacizumab) prescribing information. South San Francisco (CA):Genentech Inc; 2004 [updated 2016 Dec; cited 2016 Dec14]. Available from:http://www.gene.com/download/pdf/avastin_prescribing.pdf
11. F. Hoffmann-La Roche Ltd. Avastin (bevacizumab) summary of product characteristics. Basel:European Medicines Agency; 2015 [updated 2016 Jul 19; cited 2016 Dec 20]. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf
12. International Council on Harmonisation (ICH). Comparability of biotechnological/biological products subject to changes in their manufacturing process (Q5E):quality of biotechnological products. Geneva:ICH; 2005 [updated 2004 Nov; cited 2016 Dec20]. Available from:http://www.ich.org/products/guidelines/quality/quality-single/article/comparability-of-biotechnologicalbiological-products-subject-to-changes-in-their-manufacturing-proc.html
13. US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. Silver Spring (MD):US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); 2015 [updated 2015 Apr; cited 2016 Dec 20]. Available from:http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291128.pdf
14. Lipsky MS, Sharp LK. From idea to market:the drug approval process. J Am Board Fam Pract. 2001;14:362–367. Epub 2001/09/27
15. Nitin Kashyap U, Gupta V, Raghunandan HV. Comparison of drug approval process in United States & Europe. J Pharm Sci Res. 2013;5:131–136.
16. US Food and Drug Administration. How drugs are developed and approved. Silver Spring (MD):US Department of Health and Human Services, Center for Drug Evaluation and Research (CDER); 2015 [updated 2015 Aug 18; cited 2016 Dec 20]. Available from:http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/default.htm
17. US Food and Drug Administration. New Drug Application (NDA). Silver Spring (MD):US Department of Health and Human Services; 2016 [cited 2016 Dec 20]. Available from:http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/default.htm
18. International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonized tripartite guideline:guideline for good clinical practice. J Postgrad Med. 2001;47:45–50. Epub 2001/10/09
19. US Food and Drug Administration. Frequently asked questions on patents and exclusivity. Silver Spring (MD):US Department of Health and Human Services; 2014 [updated 2016 Dec 5; cited 2016 Dec 20]. Available from:http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079031.htm
20. Brown & Michaels PC. How do I figure out if a US patent is still in force? Ithica (NY):Brown & Michaels PC; 2015 [cited 2016 Dec 20]. Available from:http://www.bpmlegal.com/howtoterm.html
21. European Medicines Agency. Data exclusivity, market protection and paediatric rewards. Workshop for micro, small, and medium sized enterprises. London:European Medicines Agency Regulatory Affairs; 2013 [updated 2013 Apr 26; cited 2016 Oct 5]. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2013/05/WC500143122.pdf
22. US Food and Drug Administration. Abbreviated New Drug Application (ANDA):generics. Silver Spring (MD):US Department of Health and Human Services; 2016 [cited 2016 Jul 13]. Available from:http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/abbreviatednewdrugapplicationandagenerics/default.htm
23. European Medicines Agency. Guideline on similar biological medicinal products (CHMP/437/04 Rev 1). London:European Medicines Agency; 2014 [updated 2014 Oct 23; cited 2016 Dec 20]. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf
24. Health Canada. Information and submission requirements for biosimilar biologic drugs. Ottawa (ON):Ministry of Health Products and Food Branch; 2016 [updated 2016 Nov 14; cited 2017Mar 2]. Available from:http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/brgtherap/applic-demande/guides/seb-pbu/seb-pbu-2016-eng.pdf
25. World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). Geneva:Expert Committee on Biological Standardization; 2009 [updated 2009 Oct 23; cited 2016 Jun 10]. Available from:http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf
26. Zuniga L, Calvo B. Biosimilars approval process. Regul Toxicol Pharmacol. 2010;56:374–377. Epub 2009/11/21
27. Socinski MA, Curigliano G, Jacobs I, et al. Clinical considerations for the development of biosimilars in oncology. Mabs. 2015;7:286–293. Epub 2015/01/27
28. Azevedo V, Hassett B, Fonseca JE, et al. Differentiating biosimilarity and comparability in biotherapeutics. Clinical Rheumatology. 2016;35:2877–2886. Epub 2016/10/14
29. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance:non-clinical and clinical issues. London:European Medicines Agency; 2014 [updated 2014 Dec 18; cited 2017 Mar 2]. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf
30. European Medicines Agency. European public assessment report (EPAR) summary of product characteristics:Remicade (infliximab). London:European Medicines Agency Committee of Medicinal Products for Human USE (CHMP); 2009 [updated 2015 Nov 26; cited 2016 Dec 20]. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdf
31. Choe JY, Prodanovic N, Niebrzydowski J, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76:58–64. Epub 2015/09/01
32. European Medicines Agency. European public assessment report (EPAR) summary of product characteristics:flixabi (infliximab). Chertsey:Samsung Bioepis UK Limited; 2016 [updated 2016 Nov15; cited 2017 Mar 6]. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004020/WC500208356.pdf
33. Macdonald JC, Hartman H, Jacobs IA. Regulatory considerations in oncologic biosimilar drug development. Mabs. 2015;7:653–661. Epub 2015/05/12
34. Generics and Biosimilars Initiative (GaBI) Online. Biosimilar infliximab launched in Japan [media release]. Mol:Pro PharmaCommunications International; 2014 [updated 2014 Dec5; cited 2016 May 10]. Available from:http://www.gabionline.net/Biosimilars/News/Biosimilar-infliximab-launched-in-Japan
35. Baer IWH, Maini A, Jacobs I. Barriers to the access and use of rituximab in patients with non-Hodgkin’s lymphoma and chronic lymphocytic leukemia:a physician survey. Pharmaceuticals (Basel). 2014;7:530–544. Epub 2014/05/09
36. Lammers P, Criscitiello C, Curigliano G, et al. Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars:a physician survey in the United States and emerging markets. Pharmaceuticals (Basel). 2014;7:943–953. Epub 2014/09/19
37. McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012;91:405–417. Epub 2012/02/10
38. European Medicines Agency. European Medicines Agency recommends approval of first two monoclonal-antibody biosimilars [press release]. London:European Medicines Agency; 2013 [updated 2013 Jun28; cited 2016 Dec 20]. Available from:http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001837.jsp&mid=WC0b01ac058004d5c1
39. Generics and Biosimilars Initiative (GaBi) Online. Biosimilars approved in Europe. Mol:Pro PharmaCommunications International; 2016 [updated 2016 Nov25; cited 2016 Dec 20]. Available from:http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe
40. Biogen, Samsung BioLogics. BENEPALI®, the first etanercept biosimilar referencing Enbrel®, approved in the European Union. Zug:Business Wire; 2016 [updated 2016 Jan16; cited 2016 Dec 20]. Available from:http://www.businesswire.com/news/home/20160116005011/en/BENEPALI%C2%AE-Etanercept-Biosimilar-Referencing-Enbrel%C2%AE-Approved-European
41. US Food and Drug Administration. FDA approves first biosimilar product Zarxio [media release]. Silver Spring (MD):US Department of Health and Human Services, Food and Drug Administration; 2015 [updated 2015 Mar6; cited 2016 May 11]. Available from:http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm
42. US Food and Drug Administration. FDA approves Inflectra, a biosimilar to Remicade. Silver Spring (MD):US Department of Health and Human Services; 2016 [updated 2016 Apr5; cited 2016 Jun 17]. Available from:http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm494227.htm
43. US Food and Drug Administration. FDA approves Amjevita, a biosimilar to Humira. Silver Spring (MD):US Department of Health and Human Services; 2016 [updated 2016 Sep23; cited 2016 Sep 25]. Available from:http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm522243.htm
44. Generics and Biosimilars Initiative (GaBi) Online. US$67 billion worth of biosimilar patents expiring before 2020. Mol:Pro PharmaCommunications International; [updated 2014 Jan 20; cited 2016 Dec 20]. Available from:http://www.gabionline.net/Biosimilars/General/US-67-billion-worth-of-biosimilar-patents-expiring-before-2020
45. Genetic Engineering & Biotechnology News. Biosimilars:11 drugs to watch. New Rochelle (NY):GEN; 2014 [updated 2014 May19; cited 2016 Dec 20]. Available from:http://www.genengnews.com/insight-and-intelligence/biosimilars-11-drugs-to-watch/77900135
46. IMS Institute for Healthcare Informatics. Assessing biosimilar uptake and competition in European markets. Parsippany (NJ):IMS Institute foor Healthcare Informatics; 2014 [updated 2014 Oct; cited 2016 Dec 20]. Available from:http://www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20Briefs/Assessing_biosimilar_uptake_and_competition_in_European_markets.pdf
47. Araujo FC, Goncalves J, Fonseca JE. Pharmacoeconomics of biosimilars:what is there to gain from them?. Curr Rheumatol Rep. 2016;18:50. Epub 2016/07/13
48. Bocquet F, Loubiere A, Fusier I, et al. Competition between biosimilars and patented biologics:learning from European and Japanese experience. PharmacoEconomics. 2016;34:1173–1186. Epub 2016/10/22
49. IMS Institute for Healthcare Informatics. Delivering on the potential of biosimilar medicines. The role of functioning competitive markets. Parsippany (NJ):IMS Institute for Healthcare Informatics; 2016 [updated 2016 Mar; cited 2016 Dec 20]. Available from:http://www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20Briefs/Documents/IMS_Institute_Biosimilar_Brief_March_2016.pdf
50. US Food and Drug Administration. Zarxio (filgrastim-sndz) drug approval review documents. Silver Spring (MD):US Department of Health and Human Services; 2015 [updated 2015 Mar6; cited 2016 Dec 20]. Available from:http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125553Orig1s000TOC.cfm.
51. Sorgel F, Schwebig A, Holzmann J, et al. Comparability of biosimilar filgrastim with originator filgrastim:protein characterization, pharmacodynamics, and pharmacokinetics. BioDrugs. 2015;29:123–131. Epub 2015/04/04
52. Blackwell K, Semiglazov V, Krasnozhon D, et al. Comparison of EP2006, a filgrastim biosimilar, to the reference:a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. Ann Oncol. 2015;26:1948–1953. Epub 2015/07/01
53. Holzmann J, Balser S, Windisch J. Totality of the evidence at work:the first U.S. biosimilar. Expert Opin Biol Ther. 2016;16:137–142. Epub 2015/12/05
54. Fang J, Doneanu C, Alley WR, Jr., et al. Advanced assessment of the physicochemical characteristics of Remicade® and Inflectra® by sensitive LC/MS techniques. Mabs. 2016;8:1021–1034. Epub 2016/06/05
55. Hong J, Lee Y, Lee C, et al. Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab). Mabs. 2017;9:364–382. Epub 2016/12/23
56. Jung SK, Lee KH, Jeon JW, et al. Physicochemical characterization of Remsima. Mabs. 2014;6:1163–1177. Epub 2014/12/18
57. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis:the PLANETAS study. Ann Rheum Dis. 2013;72:1605–1612. Epub 2013/05/21
58. Park W, Lee SJ, Yun J, et al. Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects:a randomized, double-blind, three-arm, parallel-group, single-dose, phase I study. Expert Rev Clin Immunol. 2015;11(Suppl 1):S25–31. Epub 2015/09/24
59. Shin D, Kim Y, Kim YS, et al. A randomized, phase I pharmacokinetic study comparing SB2 and infliximab reference product (Remicade(®)) in healthy subjects. BioDrugs. 2015;29:381–388. Epub 2015/11/19
60. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis:the PLANETRA study. Ann Rheum Dis. 2013;72:1613–1620. Epub 2013/05/21
61. Rugo HS, Barve A, Waller CF, et al. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer:a randomized clinical trial. Jama. 2017;317:37–47. Epub 2016/12/06
62. Visser J, Feuerstein I, Stangler T, et al. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs. 2013;27:495–507. Epub 2013/05/08
63. US Food and Drug Administration. Nonproprietary naming of biological products. Guidance for industry. FINAL GUIDANCE. Silver Spring (MD):U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); 2017 [updated 2017 Jan; cited 2017 Mar 2]. Available from:https://www.fda.gov/downloads/drugs/guidances/ucm459987.pdf
64. World Health Organization. World Health Organization programme on international nonproprietary names. Biological qualifier:an INN proposal. Geneva:World Health Organization; 2015 [updated 2015 Oct; cited 2016 Dec 14]. Available from:http://www.who.int/medicines/services/inn/WHO_INN_BQ_proposal_2015.pdf?ua=1
65. European Commission Health and Consumers Directorate General. Pharm 639. Summary record. Pharmaceutical Committee 71st Meeting; 2013 [updated 2013 Oct23; cited 2017 Mar 2]. Available from:http://ec.europa.eu/health/sites/health/files/files/committee/71meeting/pharm639_summary.pdf
66. European Medicines Agency. QRD general principles regarding the SmPC information for a generic/hybrid/biosimilar product. London:European Medicines Agency; 2012 [updated 2012 May 3; cited 2016 Dec 20]. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/05/WC500127589.pdf
67. US Food and Drug Administration. Labeling for biosimilar products guidance for industry. Draft guidance; 2016 [updated 2016 Mar; cited 2016 Dec20]. Available from:http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM493439.pdf
68. US Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product guidance for industry. DRAFT GUIDANCE. Silver Spring (MD):U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); 2017 [updated 2017 Jan; cited 2017 Mar2]. Available from:https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM537135.pdf
69. Tothfalusi L, Endrenyi L, Chow SC. Statistical and regulatory considerations in assessments of interchangeability of biological drug products. Eur J Health Econ. 2014;15(Suppl 1):S5–11. Epub 2014/05/17
70. Renwick MJ, Smolina K, Gladstone EJ, et al. Postmarket policy considerations for biosimilar oncology drugs. Lancet Oncol. 2016;17:e31–8. Epub 2016/01/14
71. Griffith N, McBride A, Stevenson JG, et al. Formulary selection criteria for biosimilars:considerations for US health-system pharmacists. Hosp Pharm. 2014;49:813–825. Epub 2014/12/06
72. Ventola CL. Evaluation of biosimilars for formulary inclusion:factors for consideration by P&T committees. P T. 2015;40:680–689. Epub 2015/11/05
73. Zuniga L, Calvo B. Biosimilars:pharmacovigilance and risk management. Pharmacoepidemiol Drug Saf. 2010;19:661–669. Epub 2010/06/29
74. European Medicines Agency. European public assessment reports (EPAR):human medicines. London:EMA; 2016 [updated 2016 Sep 15; cited 2016 Dec 20]. Available from:http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=Submit
75. US Food and Drug Administration. Drugs@ FDA:FDA approved drug products. Silver Spring (MD):US Department of Health and Human Services; 2016 [cited 2016 Dec20]. Available from:http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm
76. Genetic Engineering & Biotechnology News. Biosimilars:10 drugs to watch. New Rochelle (NY):GEN; 2013 [updated 2013 Apr 29; cited 2016 Dec 20]. Available from:http://www.genengnews.com/insight-and-intelligence/biosimilars-10-drugs-to-watch/77899804
77. Generics and Biosimilars Initiative (GaBi) Online. Finox submits r-FSH biosimilar application to EMA. Mol:Pro PharmaCommunications International; 2013 [updated 2013 Jan 18; cited 2016 Nov 9]. Available from:http://gabionline.net/Biosimilars/News/Finox-submits-r-FSH-biosimilar-application-to-EMA